Target ALS and AFTD have announced $5 million in grants for research by six different teams to aid in the discovery of biomarkers and viable treatments for ALS and FTD, which overlap in genetic causes and biological mechanisms. Several of the teams who were awarded these grants include former AFTD grant recipients.

Al unir fuerzas, Target ALS y AFTD están aprovechando la experiencia combinada de investigadores en dos campos, impulsando la colaboración en apoyo de las ideas más prometedoras. Estos proyectos recientemente financiados informarán y potencialmente darán como resultado tratamientos viables y los biomarcadores que se necesitan de manera crítica para permitir un diagnóstico preciso y medir la progresión de la enfermedad.

“We’re proud to join Target ALS in announcing funding for these crucial funding efforts,” AFTD CEO Susan L-J Dickinson, MSGC, said. “With the challenges that the COVID-19 pandemic is adding for the families we serve, we want them to know that we are working as hard as ever to bring momentum for a day when treatments can halt FTD and ALS in their tracks.”

haga clic aquí for more information on the research partnership, including a brief overview of each funded award.